Regenxbio (RGNX) Accumulated Expenses (2014 - 2026)
Regenxbio (RGNX) posted quarterly Accumulated Expenses of $38.4 million for Q4 2025, up 0.84% year-over-year from $38.1 million in Q4 2024, and little changed quarter-over-quarter from $38.3 million in Q3 2025.
Regenxbio (RGNX) Accumulated Expenses (2014 - 2026) Analysis & Trends
Regenxbio's Accumulated Expenses history runs 12 years deep, the most recent figure standing at $38.4 million for Q4 2025.
- In Q4 2025, Accumulated Expenses rose 0.84% year-over-year to $38.4 million; the TTM figure through Dec 2025 stood at $38.4 million (up 0.84% YoY), while the FY2025 annual figure was $38.4 million, up 0.84% from the prior year.
- Accumulated Expenses for Q4 2025 stood at $38.4 million, roughly flat from $38.3 million in the prior quarter.
- The five-year high for Accumulated Expenses was $76.1 million in Q4 2021, with the low at $8.0 million in Q1 2021.
- The 5-year median for Accumulated Expenses is $40.4 million (2024), against an average of $37.6 million.
- The sharpest annual moves came in 2022 and 2024: Accumulated Expenses jumped 507.57% in 2022, then slumped 74.5% in 2024.
- Regenxbio's Accumulated Expenses stood at $76.1 million in 2021, then sank by 38.52% to $46.8 million in 2022, then increased by 6.22% to $49.7 million in 2023, then slipped by 23.41% to $38.1 million in 2024, then rose by 0.84% to $38.4 million in 2025.
- Business Quant data shows RGNX's Accumulated Expenses at $38.4 million in Q4 2025, $38.3 million in Q3 2025, and $35.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.07 Mn |
| Dec 31, 2025 | 38.39 Mn |
| Sep 30, 2025 | 38.32 Mn |
| Jun 30, 2025 | 35.56 Mn |
| Mar 31, 2025 | 23.60 Mn |
| Dec 31, 2024 | 38.07 Mn |
| Sep 30, 2024 | 14.34 Mn |
| Jun 30, 2024 | 42.49 Mn |
| Mar 31, 2024 | 8.09 Mn |
| Dec 31, 2023 | 49.70 Mn |
| Sep 30, 2023 | 45.66 Mn |
| Jun 30, 2023 | 50.52 Mn |
| Mar 31, 2023 | 31.71 Mn |
| Dec 31, 2022 | 46.79 Mn |
| Sep 30, 2022 | 13.43 Mn |
| Jun 30, 2022 | 47.01 Mn |
| Mar 31, 2022 | 48.42 Mn |
| Dec 31, 2021 | 76.11 Mn |
| Sep 30, 2021 | 49.69 Mn |
| Jun 30, 2021 | 46.76 Mn |